ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/WA/6009-Nedlands-Linear-Clinical-Research
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
38
trial(s) found.
NCT07156136
Advanced
Phase 1
Recruiting
A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination With Standard of Care Agents in HLA-A*02:01 Positive Participants With Advanced PRAME Positive Cancers (
IMC-P115C-1005
)
bispecific T-cell engager,PRAME-targeting
Cancer
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06974110
Advanced
Phase 1
Recruiting
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors (
MOMA-341-001
)
WRN inhibitor
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06876649
Paed
Phase 4
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06830850
Advanced
Phase 1
Recruiting
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer (
HRS-5041-103
)
AR PROTAC degrader
Castrate-resistant prostate cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06804824
Advanced
Phase 1
Recruiting
A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors (
VVD-159642-01
)
RAS-PI3Kalpha inhibitor
NOT Central nervous system cancer
Solid tumour
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06789172
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors (
INVOKE
)
anti-PD-1 monoclonal antibody
prostaglandin EP2/EP4/DP1 receptor inhibitor
Colorectal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Sarcoma
Solid tumour
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
WA
6009 - Nedlands - Linear Clinical Research
NCT06736704
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors (
SNV4818-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
Breast cancer
HPV-related cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06690775
Advanced
Phase 2
Recruiting
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (
TORL123-002
)
Dexamethasone
Filgrastim
Pegfilgrastim
glucocorticoid
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06669975
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors (
AP402-101
)
bispecific p95ERBB2/4-1BB antibody
bispecific p95ERBB2/CD137 antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06634849
Advanced
Phase 1 / Phase 2
Recruiting
A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. (
PTT-4256-01
)
GPR65 inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06597721
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors (
ADCE-T02-01
)
anti-TF antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06560645
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 (
PRT7732-01
)
SMARCA2 degrader
NOT Cholangiocarcinoma
NOT Ovarian small cell carcinoma
NOT Pancreatic adenocarcinoma
Non-small cell lung cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2576 - Bowral - Southern Highlands Cancer Centre
2640 - Albury - Border Medical Oncology Research Unit
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06496178
Advanced
Phase 3
Recruiting
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (
MCLA-158-CL02
)
bispecific EGFR/LGR5 antibody
Head and neck squamous cell carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06465069
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (
NEXUS-01
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06400485
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors (
AMT-676-01
)
anti-CDH17 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06244771
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (
PROSPER
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NCT06220864
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants with Advanced Solid Tumors (
SNV1521-101
)
PARP1-selective inhibitor
Prostate cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06179160
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (
INCB161734-101
)
KRAS G12D inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NCT06112314
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (
PRISM-MEL-301
anti-PD-1 monoclonal antibody
bispecific T-cell engager,PRAME-targeting
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
NCT06016738
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (
OPERA-01
)
complete estrogen receptor antagonist
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
3630 - Shepparton - Goulburn Valley Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05969041
Advanced
Phase 1
Recruiting
MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (
MYE-Symphony
)
Trop2-targeting lipid-nanoparticles
Cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05910827
Advanced
Phase 1 / Phase 2
cohorts full
A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers (
HMBD-001-103
)
anti-EGFR monoclonal antibody
anti-ERBB3 monoclonal antibody,third generation
taxane
Squamous non-small-cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT05785754
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (
DCSZ11-101
)
anti-CD93 monoclonal antibody
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2076 - Wahroonga - Sydney Adventist Hospital (WITHDRAWN)
2170 - Liverpool - Liverpool Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Townsville - Townsville University Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (WITHDRAWN)
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05763004
Advanced
Phase 1
Recruiting
A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS 1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors (
IOS-1002-201
)
anti-PD-1 monoclonal antibody
fusion protein,LILRB2/LILRB2/KIR3DL1-targeting
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05581004
Advanced
Phase 1
Recruiting
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (
GO43860
)
unknown drug class
Gastric cancer
Head and neck squamous cell carcinoma
Melanoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05544552
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (
SURF301
)
FGFR3 inhibitor
Bladder cancer
Cancer
Carcinoma
FGFR3:alteration
Solid tumour
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Linear Clinical Research
NCT05519449
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (
PSMA-007-001
)
PSMA-tumor-activated T-cell engager
Castrate-resistant prostate cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05410145
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (
D3S-001-100
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05277051
Advanced
Phase 1
Recruiting
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors
anti-PVRIG monoclonal antibody
Cancer
WA
6009 - Nedlands - Linear Clinical Research
NCT05269316
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors (
IMP9064-101
)
ATR inhibitor
PARP inhibitor
NOT Central nervous system cancer
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research (COMPLETED)
NCT05117476
Advanced
Phase 1
Recruiting
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-
MICA
/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
anti-MICA/MICB monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
Solid tumour
VIC
3004 - Melbourne, Southbank - Alfred Health (COMPLETED)
3168 - Clayton - Monash Medical Centre (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research (COMPLETED)
NCT04956640
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors (
LOXO-RAS-20001
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
ER degrader
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3K alpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04665206
Advanced
Phase 1 / Phase 2
Recruiting
Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors (
VT3989-001
)
TEAD palmitoylation inhibitor
Mesothelioma
Non-small cell lung cancer
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04449874
Advanced
Phase 1
Recruiting
A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (
GO42144
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04262466
Advanced
Phase 1 / Phase 2
Recruiting
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers (
IMC-F106C-101
)
bispecific T-cell engager,PRAME-targeting
Solid tumour
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2031 - Randwick - Scientia Clinical Research Ltd (COMPLETED)
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03906331
Advanced
Approved for marketing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
RET-selective inhibitor
RET inhibitor
Selpercatinib
cancer therapy
cancer therapy,RET-targeting
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Non-small cell lung cancer
Pancreatic cancer
Papillary thyroid cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (36)
cohorts full (1)
Approved for marketing (1)
Recruitment Country and State
WA (36)
NSW (30)
VIC (29)
SA (18)
QLD (11)
NZ (3)
Phase
Phase 1 (21)
Phase 1 / Phase 2 (11)
Phase 2 (1)
Phase 3 (3)
Phase 4 (1)
Trial Type
Advanced (37)
Paed (1)
Cancer Therapy Class
PD-1/PD-L1
37%
PD-1
32%
EGFR
18%
KRAS
16%
ERBB2
13%
KRAS G12C
13%
PI3K alpha
11%
PRAME
8%
ER
8%
oestrogen axis
8%
PD-L1
8%
AR
5%
androgen axis
5%
PARP
5%
gp100
5%
VEGF
5%
WRN
3%
BTK
3%
HRAS
3%
HRAS G12C
3%
MEK
3%
NRAS
3%
NRAS G12C
3%
prostaglandin DP1 receptor
3%
prostaglandin EP2 receptor
3%
prostaglandin EP4 receptor
3%
4-1BB
3%
CD137
3%
GPR65
3%
TF
3%
SMARCA2
3%
LGR5
3%
Nectin4
3%
CDH17
3%
PARP1-selective
3%
KRAS G12D
3%
LAG3
3%
ERBB3
3%
CD93
3%
KIR3DL1
3%
LILRB2
3%
FGFR3
3%
PSMA
3%
B7H3
3%
PVRIG
3%
ATR
3%
MICA/MICB
3%
Trop2
3%
AKT
3%
CDK4
3%
CDK6
3%
CDK7
3%
mTOR
3%
mTORC1
3%
CTLA4
3%
YAP-TEAD
3%
SHP2
3%
RET
3%
Facility
6009 - Nedlands - Linear Clinical Research (38)
3000 - Melbourne - Peter MacCallum Cancer Centre (12)
2031 - Randwick - Scientia Clinical Research Ltd (10)
3168 - Clayton - Monash Medical Centre (10)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (8)
2109 - North Ryde - Macquarie University Hospital (7)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (7)
3004 - Melbourne, Southbank - Alfred Health (7)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
5042 - Bedford Park - Flinders Medical Centre (5)
3199 - Frankston - Peninsula Health Frankston Hospital (5)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
4120 - Greenslopes - Greenslopes Private Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
2076 - Wahroonga - Sydney Adventist Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
4032 - Chermside - The Prince Charles Hospital (2)
4215 - Southport - Tasman Oncology (2)
NA
2500 - Wollongong - Wollongong Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
6009 - Nedlands - One Clinical Research (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
3630 - Shepparton - Goulburn Valley Health (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
4812 - Townsville - Townsville University Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Breast cancer
Colorectal cancer
Lower gastrointestinal cancer
Urogenital cancer
Gastroesophageal cancer
Male genital cancers
Prostate cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Pancreatobiliary cancer
Gastric cancer
Gynaecological cancer
Breast adenocarcinoma
Castrate-resistant prostate cancer
Prostate adenocarcinoma
HPV-related cancer
Viral-related cancer
Ovarian cancer
Bladder cancer
Oesophageal cancer
Melanoma
ER-positive breast cancer
HR-positive breast cancer
Endometrial cancer
B-cell malignancy
Chronic lymphocytic leukaemia
Haematological malignancy
Leukaemia
Lymphoid leukaemia
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Dedifferentiated liposarcoma
Exocrine pancreatic cancer
Fibrosarcoma
Liposarcoma
Pancreatic adenocarcinoma
Sarcoma
Soft tissue sarcoma
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Cervical cancer
HPV16-positive cancer
Renal pelvis cancer
Triple-negative breast cancer
HER2-negative breast cancer
Squamous non-small-cell lung cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Carcinoma
FGFR3:alteration
Urothelial carcinoma
Mesothelioma
Colon adenocarcinoma
Colorectal adenocarcinoma
Differentiated thyroid carcinoma
Endocrine gland cancer
Medullary thyroid cancer
Papillary thyroid cancer
Thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy